B CELL MALIGNANCIES
Clinical trials for B CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new B CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for B CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MRNA technology takes on blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new mRNA drug that targets a protein called CD19 on cancer cells. It is for adults aged 18–70 with B-cell lymphoma or leukemia who have no standard treatment options left. The drug is given by IV or injection and aims to control the disease by helpi…
Matched conditions: B CELL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New antibody drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug, AZD5492, which helps the body's immune cells attack cancer cells. It is for adults with specific B-cell blood cancers (like lymphoma or leukemia) that have returned or not improved after at least two prior treatments. The main goals are to c…
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of immune cell therapy (4SCAR19 cells) for people with B-cell cancers that have come back or not responded to treatment. The therapy uses a patient's own modified T cells to target and attack cancer cells. The trial will check if the treatment is safe …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Supercharged immune cells take on hard-to-treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses a mix of specially designed immune cells (CAR-T cells) that target up to seven different markers on cancer cells. The goal is to see …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain blood cancers (B-cell malignancies) that have come back or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Sheba Medical Center • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New combo aims to deepen remissions in blood cancer patients
Disease control Recruiting nowThis phase 2 study tests whether adding the experimental drug emavusertib to an approved targeted therapy (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia (CLL) and related B-cell cancers. About 108 participants will receive the combination to see …
Matched conditions: B CELL MALIGNANCIES
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC